All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, Should ruxolitinib become standard of care for steroid-dependent or refractory chronic GvHD?
The standard first-line treatment for chronic GvHD includes systemic corticosteroids; however, patients who become steroid-dependent or refractory require additional treatments. Here, Zeiser reports the findings from the phase III REACH3 study on ruxolitinib versus best available therapy in patients with steroid-dependent or refractory chronic GvHD.
Read a summary of the phase III REACH3 study, here.
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox